Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Delaware

Peptide legality · Delaware · updated 2026-09-21

Are peptides legal in Delaware?

Gray area

Delaware permits peptide therapy through the standard federal framework, meaning FDA-approved peptides are legal by prescription while compounded peptides sit in a gray zone shaped by FDA rules rather than any Delaware-specific ban.

Legal status overview

Delaware permits peptide therapy through the standard federal framework, and the state has not enacted peptide-specific restrictions of its own. FDA-approved peptide medicines such as Wegovy® (semaglutide) are legal when prescribed by a licensed provider, and Delaware allows telehealth prescribing of non-controlled drugs. Compounded peptides remain available through licensed 503A pharmacies only under narrow conditions, and compounded medications are not FDA-approved, are not a generic, and have not been evaluated by the FDA. BPC-157 and similar research peptides sit in federal regulatory limbo after the FDA removed BPC-157 from Category 2 in April 2026 without yet placing it on the 503A bulk substances list. This is information, not medical or legal advice.

Key points

  • Delaware has no statute or Board of Pharmacy rule that singles out peptides, so legality tracks the federal FD&C Act framework administered by the Delaware Board of Pharmacy and the FDA. [2]
  • FDA-approved peptide products including Wegovy® (semaglutide) are legal in Delaware when prescribed by an authorized provider such as an MD, DO, NP, APRN, or PA. [3]
  • The FDA declared the semaglutide shortage resolved in February 2025, and 503A enforcement discretion for compounded copies ended April 22, 2025, narrowing lawful compounding to documented clinical need. [1]
  • Compounded semaglutide is permitted only for a documented medical reason the approved product cannot meet, and compounded medications are not FDA-approved, not a generic, and not evaluated by the FDA. [6]
  • BPC-157 was removed from FDA Category 2 effective April 23, 2026, but has not been added to the Section 503A Category 1 bulk substances list, leaving it in a compounding gap. [4]
  • An FDA advisory committee voted in July 2026 to recommend adding several peptides including BPC-157 to the 503A list, but that vote is non-binding and did not by itself authorize compounding. [5]
  • Delaware allows telehealth prescribing of non-controlled medications, so peptide prescriptions can originate from a virtual visit with a licensed provider. [3]
  • Delaware is not among the states that have issued their own restrictive board guidance on compounded GLP-1s or peptides, so the federal floor governs. [2]

Compound-by-compound status

BPC-157
Gray area
Removed from FDA Category 2 in April 2026 but not yet on the Section 503A bulk substances list; a July 2026 advisory vote to add it is non-binding, so lawful compounding remains uncertain.
GLP-1 class, for example Wegovy® (semaglutide) and Zepbound® (tirzepatide)
Gray area
FDA-approved brands are legal by prescription; compounded copies are restricted after the shortage resolution and are permitted only for documented clinical need. Compounded versions are not FDA-approved, not a generic, and not evaluated by the FDA.
TB-500 (thymosin beta-4)
Gray area
Not FDA-approved and not on the 503A bulk substances list, so it sits in the same federal compounding limbo as other research peptides.
Growth hormone / somatropin
Restricted
FDA-approved by prescription, but federal law limits human growth hormone distribution to FDA-approved indications, making off-label supply restricted.

Frequently asked questions

Are peptides legal in Delaware?

There is no Delaware law banning peptides. FDA-approved peptide medicines are legal with a valid prescription, while compounded and research peptides depend on evolving FDA compounding rules rather than a state ban.

Can I get compounded semaglutide in Delaware?

Only under limited conditions. After the FDA resolved the semaglutide shortage, 503A pharmacies may compound it only for a documented clinical reason. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA.

Is BPC-157 legal in Delaware?

BPC-157 is in a federal gray zone. It was removed from FDA Category 2 in April 2026 but is not yet on the 503A bulk substances list, so its compounding status is unsettled nationwide, including in Delaware.

Do I need an in-person visit for a peptide prescription in Delaware?

Delaware allows telehealth prescribing of non-controlled medications, so a prescription can come from a virtual visit with a licensed provider, subject to the provider's clinical judgment.

Who can prescribe peptides in Delaware?

Providers such as MDs, DOs, nurse practitioners, APRNs, and physician assistants with appropriate supervision or agreements may prescribe, consistent with Delaware licensing rules.

General information based on the sourced research above, not legal advice. For a specific situation in Delaware, consult a licensed attorney familiar with pharmaceutical law.